Background Globally, an estimated 296 million individuals live with chronic hepatitis B virus (HBV) infection, carrying ...
Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, ...
Research in systemic immune-mediated rheumatic diseases (IMRDs)—including systemic lupus erythematosus (SLE), Sjögren’s syndrome, systemic sclerosis, ...
New Fred Hutch Cancer Center viral immunologist Dr. Paul Thomas is working to turn the "incredible potential" of the immune ...
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and Liberia Key takeaways: IAVI's ...
Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...
News-Medical.Net on MSN
Experimental intranasal vaccine triggers broad immune response against multiple strains of H5N1
Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) ...
In preclinical experiments, the combination of Trastuzumab PH1 + anti-PD1 outperforms the combination of Kadcyla® + anti-PD1 with a statistically significantly greater rate of Complete Responses (74% ...
Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, ...
Nerve injuries can have long-lasting effects on the immune system that appear to differ between males and females, according ...
allAfrica.com on MSN
Nigeria: Encouraging Results From a First-in-Human Phase 1 Clinical Trial of IAVI's Lassa Vaccine Candidate Published in New England Journal of Medicine
Findings are consistent with previous studies of a similarly constructed licensed Ebolavirus vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback